SCHEMBL6901097

SCHEMBL6901097

CCc1cc(CC)c(CC)s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
MAPK1 P28482 2/20 0.35
TMIGD3 P0DMS9 2/20 0.35
ADORA1 P30542 2/20 0.35
GAA P10253 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
HSD17B10 Q99714 1/20 0.34
DAO P14920 1/20 0.33
SELE P16581 1/20 0.33
VCAM1 P19320 1/20 0.33
USP2 O75604 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MAPT P10636 1/20 0.30
HTT P42858 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
GRIN2D O15399 1/20 0.30
GRIN3B O60391 1/20 0.30
GRIN1 Q05586 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9769293 0.75 TSHR (0.34) ALDH1A1MAPK1GAAUSP2NPC1
SCHEMBL11343217 0.75 ALDH1A1 (0.40) ALDH1A1MAPK1TMIGD3ADORA1GAA
SCHEMBL20645742 0.73 USP2 (0.39) USP2
SCHEMBL9769291 0.73 USP2 (0.32) ALDH1A1USP2
SCHEMBL22789253 0.73 GAA (0.38) ALDH1A1MAPK1TMIGD3ADORA1GAA
SCHEMBL6967658 0.73 USP2 (0.47) ALDH1A1MAPK1TMIGD3ADORA1GAA
SCHEMBL11077481 0.73 SELE (0.32) ALDH1A1MAPK1TMIGD3ADORA1GAA
SCHEMBL6967703 0.73 ALDH1A1 (0.58) ALDH1A1MAPK1TMIGD3ADORA1GAA
SCHEMBL6058560 0.72 NPC1 (0.36) ALDH1A1MAPK1HSD17B10SMN1; SMN2HTT
SCHEMBL14018717 0.72 ALDH1A1 (0.47) ALDH1A1MAPK1GAACYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178101-A1 DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS THERAVANCE BIOPHARMA R&D IP, LLC 2011-07-21 US disclosed
US-4256878-A THIENYL COMPOUNDS, ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. (US) 1981-03-17 US disclosed
US-4230872-A ANTITUMOR AGENTS, THIENYL-3,7-DIMETHYLNONA-2,4,6,8-TETRAENE HOFFMANN-LA ROCHE INC. (US) 1980-10-28 US disclosed
US-4116975-A 9-THIENYL-3,7-DIMETHYLNONA-2,4,6,8-TETRAENES, ANTITUMOR HOFFMANN-LA ROCHE INC. (US) 1978-09-26 US disclosed
US-4061656-A ANTITUMOR HOFFMANN-LA ROCHE INC. (US) 1977-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178101-A1 DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS REN, AGTR1, AGTR2 ALDH1A1 2122/4885MAPK1 2243/4885TMIGD3 3987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.